EICHOR ● Recruiting

A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer

Condition: Prostate Cancer · Sponsor: Jiangsu HengRui Medicine Co., Ltd.

PhasePhase 1

Planned participants320

Who can joinMale, 18 Years to 80 Years

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and the recommended Phase II dose (RP2D) of HRS-7525.

This description comes directly from the study's public registry record.

Talk to the study team

Jianpo Lian · +0518-81220121 · jianpo.lian.jl3@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (7)

Macquarie University Hospital	Sydney, New South Wales, Australia	Not Yet Recruiting
ICON South Brisbane	Brisbane, Queensland, Australia	Not Yet Recruiting
John Flynn Private Hospital	Gold Coast, Queensland, Australia	Not Yet Recruiting
ICON Kurralta Park	Adelaide, South Australia, Australia	Not Yet Recruiting
Southern Oncology Research Uni(SOCRU)	Adelaide, South Australia, Australia	Not Yet Recruiting
Epworth Health	Melbourne, Victoria, Australia	Not Yet Recruiting
Fudan University Shanghai Cancer Center	Shanghai, Shanghai Municipality, China	Recruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →